References:

1. VENCLYXTO® Summary of Product Characteristics, available at www.medicines.ie

2. Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with treatmentnaive acute myeloid leukemia ineligible for intensive chemotherapy. Paper presented at: American Society of Hematology Annual Meeting; December 10-13, 2022; New Orleans, LA. Oral presentation 219

3. Di Nardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020:387(7):617-629

4. Roberts AW. Therapeutic development and current uses of BCL-2 inhibition. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):1-9. doi: 10.1182/hematology.2020000154. PMID: 33275682; PMCID: PMC7727569